Latest Research And Development News

Page 14 of 115
Identitii’s BNDRY platform gained customers and recurring revenue in FY26, but the company ended the year with just $107,483 in cash, negative net assets and a material uncertainty over its ability to continue as a going concern. A subsequent convertible note facility provides a committed $5 million, while access to a further $15 million remains conditional.
Victor Sage
Victor Sage
30 Sept 2026
TrivarX has made Stabl-Im its central development bet, but the ASX-listed health technology company also reported an $8.76 million FY2026 loss and an auditor-flagged material uncertainty over its ability to continue without further funding. The planned Phase 1 study remains subject to regulatory, ethics and operational clearances.
Ada Torres
Ada Torres
29 Sept 2026
Rhythm Biosciences has moved ColoSTAT and geneType into commercial use, recording its first sales during FY2026. But with sales revenue of just $85,339, a $5.93 million loss and an auditor-flagged going-concern uncertainty, the next phase will be judged on cash generation and repeat adoption.
Victor Sage
Victor Sage
29 Sept 2026
AnteoTech has received $1.905 million from the Australian R&D Tax Incentive, providing fresh cash for its battery materials and life sciences commercialisation efforts. The rebate relates to eligible research conducted during the 2026 financial year.
Sophie Babbage
Sophie Babbage
29 Sept 2026
West Cobar Metals ended FY2026 with more cash but a larger loss and an auditor-highlighted material uncertainty over its ability to continue without further funding. Exploration advanced across Salazar and Cobar West, but the company remains dependent on equity markets to keep its programmes moving.
Maxwell Dee
Maxwell Dee
29 Sept 2026
IperionX has moved its Virginia titanium operation into 24/7 production, lifting nameplate powder capacity to about 200 tonnes a year while commissioning equipment aimed at higher-value components. The progress came alongside a US$66.8 million annual loss, US$63.5 million of operating and investing cash outflows, and continued reliance on government support, customer qualification and future capital.
Victor Sage
Victor Sage
29 Sept 2026
IODM Limited (ASX:IOD) increased FY2026 revenue by 16.9% and narrowed its net loss, but auditors flagged material uncertainty over the company’s ability to continue as a going concern. A post-year-end A$1.00 million placement is funding an expansion into North American universities while the business remains heavily reliant on external capital.
Victor Sage
Victor Sage
28 Sept 2026
Patrys has moved its injectable quetiapine program into human testing, while its FY2026 annual report warns the company will need further funding within 12 months. The company ended the year with $3.36 million in cash after raising capital and acquiring the RLS-2202 development program.
Victor Sage
Victor Sage
28 Sept 2026
AnteoTech reduced its FY2026 loss and strengthened its balance sheet, but auditors warned that a material uncertainty remains over the company’s ability to continue as a going concern. Commercial revenue fell sharply as battery and diagnostics opportunities remained largely in evaluation or negotiation.
Victor Sage
Victor Sage
28 Sept 2026
ABx Group has lodged a prospectus for a fully underwritten $2 million share purchase plan, forming part of a broader $4.1 million capital raising for its Deep Leads rare earths project and ALCORE pilot plant. The offer gives eligible shareholders discounted shares and options, but leaves the final price unknown until after applications close and remains subject to shareholder approval.
Victor Sage
Victor Sage
28 Sept 2026
EMVision Medical Devices has received a $4.3 million R&D tax refund, adding non-dilutive funding as it progresses clinical work on its emu™ and First Responder devices. The cash arrives against a last reported cash balance of $17.1 million and $4.6 million in remaining grant funding at 30 June 2026.
Victor Sage
Victor Sage
28 Sept 2026
First Graphene expanded its product range and international footprint in FY2026, lifting revenue while narrowing its annual loss. But the company says continued operations depend on securing further equity funding, putting commercial execution and liquidity at the centre of its next phase.
Victor Sage
Victor Sage
25 Sept 2026

Browse the archive

Full archive